Sarcoma / 2015 / Article / Tab 1

Review Article

Medication Exposures and Subsequent Development of Ewing Sarcoma: A Review of FDA Adverse Event Reports

Table 1

Summary of FAERS reports of medication use prior to Ewing Sarcoma Family of Tumor (ESFT) diagnosis, 1997–2013. Total = 25; 13 US, 12 foreign; 16 females, 9 males. Ages 4–68 years (median age 24 years; mean 30 years). Known latency for 20 patients: 3 months–12 years (median 27 months; mean 3.2 years); 5 unknown.

Report year Number of cases



Drug useNumber of casesPatient age (yrs)Latency

Immunosuppressive125–68Mean 4.2 years, median 4 years
Growth hormone (GH) 211, 164 months after 5 years therapy, 18 months
Estrogen/progestin224, 4710 months, 2.5 years
CNS depressant234, 4222 months, unknown
Atypical antipsychotic 117No information
Antiepileptic1 88 years
Antipsychotic and AED1193 months
ADHD1 8No information
Isotretinoin12010 months
Statin for hyperlipidemia 1 9>2 years
rPTH1491 year

1 Crohn’s patient also received GH.
rPTH, recombinant parathyroid hormone.

Underlying conditions

12 Immune-related3 Crohn’s disease, 3 multiple sclerosis, 1 renal transplant, 1 rheumatoid arthritis, 1 nephrotic syndrome, 1 ankylosing spondylitis, 1 psoriasis vulgaris, and 1 chronic hepatitis B

5 Endocrine2 growth disorders, 1 menopause, 1 osteoporosis, and 1 birth control (patient morbidly obese but no underlying condition reported)

3 Neurologic1 each of narcolepsy, seizure disorder, and fibromyalgia with sciatica/neuropathic pain

3 Psychiatric1 each of unspecified depression, psychoses, and ADHD

2 Other1 each of familial hypercholesterolemia, acne

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.